Denali Therapeutics CMO sells 1,654 shares

Denali Therapeutics’ chief medical officer sold shares to cover RSU-related taxes and continues to hold over 200,000 shares, including a large unvested RSU position.

Rhea-AI Filing Summary

Denali Therapeutics Inc. (DNLI) reported that Chief Medical Officer Peter Scott Chin sold 1,654 shares of common stock on September 4, 2026 at a weighted average price of $22.29 per share. The shares were sold to satisfy tax obligations related to settlement of previously vested restricted stock units, and he now holds 204,538 shares, including 142,845 unvested RSUs and 1,790 shares acquired under the ESPP on June 1, 2026. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 1,654 shares

Net Sell 1 txn

Insider Chin Peter Scott

Role Chief Medical Officer

Sold 1,654 shs ($37K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3, F4	1,654	$22.29	$37K

Holdings After Transaction: Common Stock — 204,538 shares (Direct)

Footnotes (4)

1. F1. Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
2. F2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. Includes 142,845 Unvested RSU's
4. F4. Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.

Key Figures

Shares sold: 1,654 shares Weighted average sale price: $22.29 per share Shares owned after transaction: 204,538 shares +2 more

5 metrics

Shares sold 1,654 shares Common stock sale on September 4, 2026

Weighted average sale price $22.29 per share Sale prices ranged from $22.28 to $22.29 per share

Shares owned after transaction 204,538 shares Post-transaction beneficial ownership of the CMO

Unvested RSUs included in holdings 142,845 RSUs Unvested restricted stock units included in post-transaction total

ESPP shares included in holdings 1,790 shares Shares acquired under ESPP purchase on June 1, 2026

Key Terms

restricted stock units, weighted average sale price, ESPP

3 terms

restricted stock units financial

"tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The sale price reported in column 4 represents the weighted average sale price"

ESPP financial

"Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026"

An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Denali Therapeutics (DNLI) disclose for September 4, 2026?

Denali Therapeutics disclosed that Chief Medical Officer Peter Scott Chin sold 1,654 shares of common stock on September 4, 2026 at a weighted average price of $22.29 per share to satisfy tax obligations from previously vested RSUs.

Why did the Denali Therapeutics (DNLI) CMO sell 1,654 shares?

The 1,654 shares were sold by Denali Therapeutics’ Chief Medical Officer to satisfy tax obligations arising from the settlement of previously vested restricted stock units, according to the filing footnotes.

How many Denali Therapeutics (DNLI) shares does the CMO hold after this Form 4 transaction?

After the reported sale, the Chief Medical Officer beneficially owns 204,538 shares of Denali Therapeutics common stock, which includes 142,845 unvested RSUs and 1,790 shares acquired under the ESPP on June 1, 2026.

What was the price range for the Denali Therapeutics (DNLI) insider share sale?

The reported sale price reflects a weighted average of $22.29 per share, with individual sale prices ranging from $22.28 to $22.29 per share, as disclosed in the transaction footnote.

Was the Denali Therapeutics (DNLI) insider sale made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is associated with this transaction; the shares were sold specifically to cover RSU-related tax obligations.

Does the Denali Therapeutics (DNLI) CMO still have unvested equity after this sale?

Yes. Following the sale, the Chief Medical Officer’s holdings include 142,845 unvested restricted stock units (RSUs), in addition to other common shares, as reflected in the post-transaction ownership footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:45 PM Accepted by SEC EDGAR 09/09/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chin Peter Scott

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BOULEVARD, SECOND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		S(1)		1,654	D	$22.29(2)	204,538(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. Includes 142,845 Unvested RSU's

4. Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)